IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Kroczek

Application No.: 09/509,283	Group Art Unit: 1644
Filed: August 11, 2001	Examiner: J. Roark
For: ANTI-HUMAN T-CELL COSTIMULATING POLYPEPTIDE MONOCLONAL ANTIBODIES	Attorney Docket No.: 7853-215

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

BOX SEQUENCE LISTING
Assistant Commissioner for Patents
Washington, DC 20231

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures ("Notice to Comply") mailed by the U.S. Patent and Trademark Office on October 19, 2001 in connection with the above-identified application, Applicant submits herewith a second substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. § 1.821 and a copy of the Notice to Comply.

The substitute paper copy and computer readable forms of the "Sequence Listing" submitted herewith correct the typographical error noted in the Notice To Comply.

I hereby state that the content of the paper and computer readable copies of the substitute Sequence Listing, submitted herewith in accordance with 37 C.F.R. §1.821, are the same. I hereby state that the submission herein does not include new matter.

Applicant further submits herewith a Petition for Extension of Time for responding to the Notice to Comply.

Respectfully submitted,

Date   December 12, 2001   *Laura A. Coruzzi*   30,742

                                                                      Laura A. Coruzzi   (Reg. No.)

By: *Muna Abu-Shaar*

Muna Abu-Shaar
Limited Recognition Under 37 C.F.R. § 10.9(b)
Copy of Certificate Enclosed

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

2

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Ms. Muna Abu-Sha'ar is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Pennie & Edmonds, LLP to prepare and prosecute patent applications wherein the patent applicant is the client of Pennie & Edmonds, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of Pennie & Edmonds, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Ms. Muna Abu-Sha'ar ceases to lawfully reside in the United States, (ii) Ms. Muna Abu-Sha'ar's employment with Pennie & Edmonds, LLP ceases or is terminated, or (iii) Ms. Muna Abu-Sha'ar ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: June 30, 2002

Harry Moatz, Director
Office of Enrollment and Discipline

	Application No.	Applicant(s)
Notice to Comply	09/509,283	KROCZEK, RICHARD
	Examiner	Art Unit
	Jessica H. Roark	1644

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: Newly submitted SEQ ID NO:2 does not correspond to original SEQ ID NO:2, nor does it correspond to the encoding nucleic acid sequence in SEQ ID NO:1. The error appears to be at position 151, or possibly 152 or 153, of instant SEQ ID NO:2 - a Val has been ommitted versus the originally filed sequence listing.

Applicant Must Provide:
☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
    Technical Assistance...703-287-0200
    To Purchase PatentIn Software.......................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

#18

1600

RAW SEQUENCE LISTING   DATE: 12/13/2001
PATENT APPLICATION: US/09/509,283A   TIME: 16:30:00

Input Set : A:\7853215999.txt
Output Set: N:\CRF3\12132001\I509283A.raw   **ENTERED**

```
 3 <110> APPLICANT: Kroczek, Richard
 5 <120> TITLE OF INVENTION: Anti-human T-cell costimulating monoclonal antibodies
 7 <130> FILE REFERENCE: 7853-215
 9 <140> CURRENT APPLICATION NUMBER: 09/509,283A
10 <141> CURRENT FILING DATE: 2000-08-11
12 <160> NUMBER OF SEQ ID NOS: 4
14 <170> SOFTWARE: PatentIn version 3.0
16 <210> SEQ ID NO: 1
17 <211> LENGTH: 2641
18 <212> TYPE: DNA
19 <213> ORGANISM: 8F4
21 <220> FEATURE:
22 <221> NAME/KEY: CDS
23 <222> LOCATION: 68..667
25 <400> SEQUENCE: 1
26 cgagagcctg aattcactgt cagctttgaa cactgaacgc gaggactgtt aactgtttct       60
27 ggcaaac atg aag tca ggc ctc tgg tat ttc ttt ctc ttc tgc ttg cgc      109
28         Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg
29          1               5                  10
30 att aaa gtt tta aca gga gaa atc aat ggt tct gcc aat tat gag atg      157
31 Ile Lys Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met
32 15                  20                  25                  30
33 ttt ata ttt cac aac gga ggt gta caa att tta tgc aaa tat cct gac      205
34 Phe Ile Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp
35                  35                  40                  45
36 att gtc cag caa ttt aaa atg cag ttg ctg aaa ggg ggg caa ata ctc      253
37 Ile Val Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu
38                  50                  55                  60
39 tgc gat ctc act aag aca aaa gga agt gga aac aca gtg tcc att aag      301
40 Cys Asp Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys
41          65                  70                  75
42 agt ctg aaa ttc tgc cat tct cag tta tcc aac aac agt gtc tct ttt      349
43 Ser Leu Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe
44       80                  85                  90
45 ttt cta tac aac ttg gac cat tct cat gcc aac tat tac ttc tgc aac      397
46 Phe Leu Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn
47 95                  100                 105                 110
48 cta tca att ttt gat cct cct cct ttt aaa gta act ctt aca gga gga      445
49 Leu Ser Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly
50                  115                 120                 125
51 tat ttg cat att tat gaa tca caa ctt tgt tgc cag ctg aag ttc tgg      493
52 Tyr Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp
53                  130                 135                 140
54 tta ccc ata gga tgt gca gcc ttt gtt gta gtc tgc att ttg gga tgc      541
55 Leu Pro Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys
56                  145                 150                 155
57 ata ctt att tgt tgg ctt aca aaa aag aag tat tca tcc agt gtg cac      589
```

```
58 Ile Leu Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His
59         160                 165                 170
60 gac cct aac ggt gaa tac atg ttc atg aga gca gtg aac aca gcc aaa        637
61 Asp Pro Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys
62 175                 180                 185                 190
63 aaa tct aga ctc aca gat gtg acc cta taa tatggaactc tggcacccag          687
64 Lys Ser Arg Leu Thr Asp Val Thr Leu
65                 195
66 gcatgaagca cgttggccag ttttcctcaa cttgaagtgc aagattctct tatttccggg      747
67 accacggaga gtctgactta actacataca tcttctgctg gtgttttgtt caatctggaa      807
68 gaatgactgt atcagtcaat ggggatttta acagactgcc ttggtactgc cgagtcctct      867
69 caaaacaaac accctcttgc aaccagcttt ggagaaagcc cagctcctgt gtgctcactg      927
70 ggagtggaat ccctgtctcc acatctgctc ctagcagtgc atcagccagt aaaacaaaca      987
71 catttacaag aaaaatgttt taaagatgcc aggggtactg aatctgcaaa gcaaatgagc     1047
72 agccaaggac cagcatctgt ccgcatttca ctatcatact acctcttctt tctgtaggga     1107
73 tgagaattcc tcttttaatc agtcaaggga gatgcttcaa agctggagct attttatttc     1167
74 tgagatgttg atgtgaactg tacattagta cactcagt actctccttc aattgctgaa       1227
75 ccccagttga ccattttacc aagactttag atgctttctt gtgccctcaa tttttctttt     1287
76 aaaaatactt ctacatgact gcttgacagc ccaacagcca ctctcaatag agagctatgt     1347
77 cttacattct ttcctctgct gctcaatagt tttatatatc tatgcataca tatatacaca     1407
78 catatgtata taaaattcat aatgaatata tttgcctata ttctccctac aagaatattt     1467
79 ttgctccaga aagacatgtt cttttctcaa attcagttaa aatggtttac tttgttcaag     1527
80 ttagtggtag aaacattgc ccggaattga aagcaaattt attttattat cctattttct      1587
81 accattatct atgttttcat ggtgctatta attacaagtt tagttctttt tgtagatcat     1647
82 attaaaattg caaacaaaat catctttaat gggccagcat tctcatgggg tagagcagaa     1707
83 tattcattta gcctgaaagc tgcagttact ataggttgct gtcagactat acccatggtg     1767
84 cctctgggct tgacaggtca aaatggtccc catcagcctg gagcagccct ccagacctgg     1827
85 gtggaattcc agggttgaga gactcccctg agccagaggc cactaggtat tcttgctccc     1887
86 agaggctgaa gtcaccctgg gaatcacagt ggtctacctg cattcataat tccaggatct     1947
87 gtgaagagca catatgtgtc agggcacaat tccctctcat aaaaaccaca cagcctggaa     2007
88 attggccctg gcccttcaag atagccttct ttagaatatg atttggctag aaagattctt     2067
89 aaatatgtgg aatatgatta ttcttagctg gaatattttc tctacttcct gtctgcatgc     2127
90 ccaaggcttc tgaagcagcc aatgtcgatg caacaacatt tgtaacttta ggtaaactgg     2187
91 gattatgttg tagtttaaca ttttgtaact gtgtgcttat agtttacaag tgagacccga     2247
92 tatgtcatta tgcatactta tattatctta agcatgtgta atgctggatg tgtacagtac     2307
93 agtactgaac ttgtaatttg aatctagtat ggtgttctgt tttcagctga cttggacaac     2367
94 ctgactggct ttgcacaggt gttccctgag ttgtttgcag gtttctgtgt gtggggtggg     2427
95 gtatggggag gagaaccttc atggtggccc acctggcctg gttgtccaag ctgtgcctcg     2487
96 acacatcctc atccccagca tgggacacct caagatgaat aataattcac aaaatttctg     2547
97 tgaaatcaaa tccagtttta agaggagcca cttatcaaag agattttaac agtagtaaga     2607
98 aggcaaagaa taaacatttg atattcagca actg                                 2641
100 <210> SEQ ID NO: 2
101 <211> LENGTH: 199
102 <212> TYPE: PRT
103 <213> ORGANISM: 8F4
105 <400> SEQUENCE: 2
106 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
107 1               5                   10                  15
109 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
```

```
110                 20                25                30
112 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
113         35                40                45
115 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
116         50                55                60
118 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
119 65                70                75                80
121 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
122                 85                90                95
124 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
125                 100               105               110
127 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
128         115               120               125
130 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
131         130               135               140
133 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
134 145               150               155               160
136 Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro
137                 165               170               175
139 Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
140                 180               185               190
142 Arg Leu Thr Asp Val Thr Leu
143         195
145 <210> SEQ ID NO: 3
146 <211> LENGTH: 17
147 <212> TYPE: PRT
148 <213> ORGANISM: 8F4
150 <400> SEQUENCE: 3
151 Met Gly Asn Cys Thr Ser Ala Cys Asn Gly Ala Tyr Gly Thr Asn Ala
152 1               5                 10                15
153 Cys
155 <210> SEQ ID NO: 4
156 <211> LENGTH: 17
157 <212> TYPE: PRT
158 <213> ORGANISM: 8F4
160 <400> SEQUENCE: 4
162 Met Gly Asn Tyr Thr Asp Ala Cys Asn Gly Ala Tyr Gly Thr Asn Ala
163 1               5                 10                15
164 Cys
```

VERIFICATION SUMMARY   DATE: 12/13/2001
PATENT APPLICATION: US/09/509,283A   TIME: 16:30:01

Input Set : **A:\7853215999.txt**
Output Set: **N:\CRF3\12132001\I509283A.raw**